Business Context and Reporting Period
This Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on July 21, 2016, reporting the satisfaction of closing conditions for a strategic partnership. The filing details the effectiveness of a License and Collaboration Agreement and a related Common Stock Purchase Agreement with Takeda Pharmaceutical Company Limited, originally announced on June 6, 2016.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the equity transaction with Takeda:
- Total Consideration: $40,000,000
- Shares Purchased: 374,590 shares of common stock
- Effective Per-Share Price: $106.78
- Pricing Structure: $25,000,000 based on the 30-day volume weighted-average price prior to June 6, 2016, plus a $15,000,000 premium.
- Transaction Date: The Initial Purchase was completed on July 26, 2016.
Material Changes
The material change reported is the formal closing of the collaboration and equity purchase with Takeda. The agreements became effective on July 21, 2016, following the satisfaction of Hart-Scott-Rodino Antitrust Improvements Act approval and other customary closing conditions.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard closing conditions mentioned. The document focuses strictly on the execution of the previously announced agreements.
Key Facts for Investor Verification
- Verify the impact of the $40 million capital raise on the company's cash position and dilution.
- Confirm the specific terms of the License and Collaboration Agreement regarding future milestones or royalties, which are not detailed in this 8-K.
- Monitor the completion of the Initial Purchase on July 26, 2016, and any subsequent tranches if applicable.
- Review the 30-day volume weighted-average price calculation used to determine the base purchase price.